{"id":18371,"date":"2026-06-09T22:00:00","date_gmt":"2026-06-09T20:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=382413bcc36f4e0515a44c71746d68dc"},"modified":"2026-06-09T22:00:00","modified_gmt":"2026-06-09T20:00:00","slug":"covalon-announces-appointment-of-new-director-and-dsu-grants","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18371","title":{"rendered":"Covalon Announces Appointment of New Director and DSU Grants"},"content":{"rendered":"

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the \u201cCompany\u201d or \u201cCovalon\u201d) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the appointment of Dr. Murray Miller to its Board of Directors (\u201cBoard\u201d) as an independent director subject to TSX Venture Exchange approval.<\/p><\/a><\/a>

\nDr. Miller graduated as a Medical Doctor from the University of Manitoba in 1982. He completed his residency in Radiology at the University of Toronto. Dr. Miller has served as a physician and practice leader at Ontario hospitals and community clinics since then. Dr. Miller has held leadership positions in medical associations and has served as an advisor to a number of biotech and medical technology companies.<\/p>

\n\u201cI am delighted that Dr. Miller has agreed to rejoin the Covalon Board of Directors. Having previously served on our Board between 2010 and 2019, Dr. Miller is very knowledgeable about Covalon and has remained a substantial shareholder. Covalon will benefit greatly from his medical expertise and creative energy in the further advancement of our Company\u201d, said Abe Schwartz, Chair of the Covalon Board.<\/p>

\nIn connection with the appointment of Dr. Miller to the Board, the Company has granted to Dr. Miller an aggregate of 22,222 Deferred Share Units (\u201cDSUs\u201d) for all of Dr. Miller\u2019s annual director\u2019s fees for fiscal year 2026 as opposed to cash. The DSUs were granted under the Company\u2019s Amended and Restated Omnibus Long-Term Incentive Plan (the \u201cLTIP\u201d) adopted effective on March 25, 2026. The DSUs will vest 12 months from the date of grant. The deemed value for the DSUs was calculated using the closing price of the Company\u2019s common shares on the TSX Venture Exchange on June 8, 2026, being $2.16 multiplied by the number of DSUs awarded.<\/p>

\nIn addition, the Company has also granted a total of 6,218 DSUs to certain directors to settle its obligations under the Company\u2019s LTIP.<\/p>

\nThose interested in learning more about Covalon can visit www.covalon.com<\/a> or follow Covalon on LinkedIn<\/a>, Facebook<\/a>, Instagram<\/a>, or X<\/a>.<\/p>

\nAbout Covalon\nCovalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com<\/a>.<\/p>

\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/p>

\nThis news release may contain forward-looking statements which reflect the Company\u2019s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as \u201cseek\u201d, \u201canticipate\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cintend\u201d, or variations of such words and phrases or state that certain actions, events, or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cwill\u201d or \u201cwill be taken\u201d, \u201coccur\u201d, or \u201cbe achieved\u201d. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management\u2019s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the \u201cRisks and Uncertainties\u201d section of our management\u2019s discussion and analysis of financial condition and results of operations for the year ended September 30, 2025, which is available on the Company\u2019s profile at <\/i>www.sedarplus.ca<\/i><\/a>, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.<\/i><\/p> Contacts<\/b>

\nTo learn more about Covalon, please contact:\n\nBrent Ashton, Chief Executive Officer, Covalon Technologies Ltd.\nEmail: investors@covalon.com<\/a>Phone: 1.877.711.6055\nWebsite: https:\/\/covalon.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the \u201cCompany\u201d or \u201cCovalon\u201d) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the appointment of Dr. Murray Miller to its Board of Directors (\u201cBoard\u201d) …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18371","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18371"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18371\/revisions"}],"predecessor-version":[{"id":18372,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18371\/revisions\/18372"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}